RLMD
NASDAQ · Pharmaceuticals
Relmada Therapeutics Inc
$7.32
-0.11 (-1.48%)
Open$7.48
Previous Close$7.43
Day High$7.50
Day Low$7.21
52W High$8.00
52W Low$0.32
Volume—
Avg Volume887.5K
Market Cap779.32M
P/E Ratio—
EPS$-1.50
SectorPharmaceuticals
Analyst Ratings
Strong Buy
11 analysts
Price Target
+410.5% upside
Current
$7.32
$7.32
Target
$37.37
$37.37
$22.23
$37.37 avg
$43.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 81.98M | 84.82M | 68.85M |
| Net Income | 12.35M | 12.13M | 11.14M |
| Profit Margin | 15.1% | 14.3% | 16.2% |
| EBITDA | 16.29M | 17.92M | 12.74M |
| Free Cash Flow | 15.25M | 10.32M | 8.64M |
| Rev Growth | +24.2% | +0.2% | +22.0% |
| Debt/Equity | 0.79 | 0.99 | 1.00 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $948.45 | -2.72% | 36.1 | 913.24B |
| JNJ | Johnson & Johnson | $221.32 | -0.53% | 26.1 | 548.94B |
| MRK | Merck & Co. Inc. | $111.38 | -0.82% | 31.3 | 279.42B |
| PFE | Pfizer Inc. | $25.68 | -3.02% | 19.3 | 150.09B |
| BMY | Bristol-Myers Squibb Co | $56.16 | -0.16% | 17.0 | 120.08B |
| ZTS | Zoetis Inc | $82.83 | -5.13% | 21.5 | 57.37B |